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classification of rare arrhythmogenic and conduc‑
tion disorders, and rare arrhythmias (RACDRAs) 
included in the recently revised RCDDs classifica‑
tion.4 RACDRAs are often undervalued and clini‑
cal practice guidelines include many uncertainties 
in this field, including those associated with car‑
diovascular implantable electronic devices.5-9 This 
updated classification will be valuable in planning 
further large ‑scale clinical studies, which may lead 
to improved care in patients with RACDRAs.
INTRODUCTION Rare cardiovascular diseases and 
disorders (RCDDs) constitute an important clinical 
problem, and their proper classification is crucial 
for expanding knowledge in the field of RCDDs. 
This classification provides an overview of RCDDs, 
which may also facilitate creation of databases and 
improved data gathering from various clinical cen‑
ters.1 The first clinical classification of RCDDs was 
published in 2013 in the Journal of Rare Cardiovas‑
cular Diseases.2,3 We aimed to provide an updated 
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ABSTRACT
INTRODUCTION Rare cardiovascular diseases and disorders (RCDDs) constitute an important clinical 
problem, and their proper classification is crucial for expanding knowledge in the field of RCDDs. 
OBJECTIVES The aim of this paper is to provide an updated classification of rare arrhythmogenic and 
conduction disorders, and rare arrhythmias (RACDRAs).
METHODS We performed a search for RACDRAs using the Orphanet inventory of rare diseases, which 
includes diseases with a prevalence of no more than 5 per 10 000 in the general population. We supple‑
mented this with a search of PubMed and Scopus databases according to a wider definition proposed 
by the European Parliament and the Council of the European Union.
RESULTS RACDRAs are categorized into 2 groups, primary electrical disorders of the heart and ar‑
rhythmias in specific clinical settings. The first group is further divided into subgroups of major clinical 
presentation: disorders predisposing to supraventricular tachyarrhythmias, ventricular tachyarrhythmias, 
bradyarrhythmias, and others. The second group includes iatrogenic arrhythmias or heart rhythm distur‑
bances related to medical treatment, arrhythmias associated with metabolic disorders, and others. We 
provide a classification of RACDRAs and supplement them with respective RCDDs codes.
CONCLUSION The clinical classification of RACDRAs may form a basis to facilitate research and progress 
in clinical practice, both in diagnostic and therapeutic approaches.
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Clinical classification of rare arrhythmogenic and 
conduction disorders, and rare arrhythmias RAC‑
DRAs constitute class VI of the clinical classifi‑
cation of RCDDs.4 The principal group of RAC‑
DRAs is primary electrical disorders of the heart. 
This is further divided into subgroups by major 
clinical presentation: disorders associated with 
supraventricular tachyarrhythmias,15 ventricu‑
lar tachyarrhythmias,16 bradyarrhythmias, and 
others (TABLE 1).17,18-20 Moreover, common patho‑
physiology, choice of therapy, risk stratification, 
and clinical prognosis were considered in creat‑
ing the subgroups.
Within the subgroup of rare disorders poten‑
tially associated with supraventricular tachyar‑
rhythmias, several types of arrhythmogenic dis‑
orders were distinguished. These included: preex‑
citation syndromes (such as Mahaim syndrome21 
and enhanced atrioventricular nodal conduction, 
known previously as Lown–Ganong–Levine syn‑
drome),22 permanent form of junctional recipro‑
cating tachycardia (Coumel tachycardia),23 multi‑
focal atrial tachycardia,24 and His bundle tachycar‑
dia (junctional ectopic tachycardia).25 Atrioventric‑
ular nodal reentrant tachycardia (AVNRT) preva‑
lence is about 22.5 per 10 000 persons.26 However, 
atypical forms of AVNRT, including fast ‑slow and 
slow ‑slow AVNRT, are rare and comprise about 
6.4% of patients. It should be noted that some pa‑
tients with AVNRT may not be reliably classified 
because of electrophysiological characteristics.27 
We also introduced double fire tachycardia (dual 
atrioventricular nodal nonreentrant tachycardia) 
into the group of disorders predisposing to supra‑
ventricular tachyarrhythmias.28 There are sparse 
epidemiological data on specific supraventricu‑
lar tachycardias.29 However, considering the in‑
cidence of atrial flutter of 8.8 per 10 000 person‑
‑years in the general population,30 it seems that 
atypical atrial flutter is rare (TABLE 1). Moreover, de‑
spite limited epidemiological evidence and possi‑
ble underdiagnosis, we included sinoatrial reentry 
tachycardia into RACDRAs.31 On the other hand, 
atrial tachycardia is the third most common spe‑
cific supraventricular tachycardia and was not in‑
cluded in the RACDRAs.32 Due to the relatively 
high prevalence of the Wolff–Parkinson–White 
syndrome and improvements in its treatment, it 
was excluded from the current classification.33,34 
However, familial forms of the Wolff–Parkinson–
White syndrome35 and AVNRT36,37 seem to be 
rare and it appears to be appropriate to consider 
them as RACDRAs (RCDDs codes, VI ‑1A ‑1.0 and 
VI ‑1A ‑2.0, respectively). On the other hand, it 
is questionable whether familial forms of AF 
(ORPHA number 334)38,39 or inappropriate si‑
nus tachycardia40 should be included in the cur‑
rent classification, because of their frequency, 
rare genetic testing, and potential underdiag‑
nosing. Due to its high prevalence, we did not in‑
clude interatrial block, which is a predictor of AF, 
into RACDRAs classification. In the Atheroscle‑
rosis Risk in Communities (ARIC)41 study, per‑
formed in a population at a mean age of 54 years, 
The definition of a rare disease as proposed 
by the European Parliament and the Council 
of the European Union, supported, as a guide, 
a threshold for rare disease prevalence of no 
more than 5 per 10 000 individuals in the gen‑
eral population (Regulation [EC] No 141/2000 
of the European Parliament and of the Coun‑
cil on orphan medicinal products). This defini‑
tion emphasized that in the case of rare diseases, 
the scale of the health problem is so small that 
it requires combined efforts to perform neces‑
sary analyses or effective interventions.10 RCDDs 
and RACDRAs are in line with this definition. In 
addition, these disorders impact patient quality 
of life and/or mortality and insufficient knowl‑
edge about them may result in unfavorable clini‑
cal outcomes. Moreover, RACDRAs often require 
multidisciplinary management.
METHODS We performed a search for RAC‑
DRAs using the Orphanet inventory of rare dis‑
eases, which includes diseases that have a preva‑
lence of no more than 5 per 10 000 individuals in 
the general population.11 We supplemented this 
with a search of PubMed and Scopus databases ac‑
cording to a wider definition proposed by the Eu‑
ropean Parliament and the Council of the Euro‑
pean Union. The following keywords were used 
to search PubMed and Scopus databases: “rare” 
OR “rarity” AND “arrhythmia” OR “arrhythmo‑
genic” OR “cardiac conduction” OR “myocardi‑
al conduction” OR “heart conduction” AND “dis‑
order” OR “disease” OR “syndrome.” Initially, we 
have found over 3700 documents in PubMed and 
over 5100 documents in Scopus. This approach is 
in line with our methodology and appears to be 
more useful in clinical practice and should fur‑
ther improve research relating to RCDDs. An im‑
portant limitation of the approach to rare dis‑
eases based only on the frequency of the disease 
is that their prevalence varies or is unknown de‑
pending on regions of the world. This limitation 
also applies to RACDRAs and is clearly illustrat‑
ed by the differences in the prevalence of Bruga‑
da syndrome (BrS).12,13
In the updated classification, we aimed to min‑
imize the repetition of diagnoses and to include 
more diseases and disorders. Therefore, the pre‑
vious group of arrhythmias of atypical mecha‑
nism and electrocardiographic presentation was 
removed, and those diseases were moved into 
other appropriate subgroups. Because arrhyth‑
mic manifestations are varied and frequently 
more than one arrhythmia is present, a sample 
International Classification of Diseases and Relat‑
ed Health Problems, 10th Revision (ICD ‑10) code 
was provided for each disease or condition to 
ensure clarity.14 For diseases present in the Or‑
phanet inventory of rare diseases (available at: 
http://www.orpha.net/consor/cgi‑bin/Disease.
php?lng=EN), ORPHA numbers were added to 
enable search and direct comparison of the clas‑
sified diseases and disorders in the Orphanet in‑
ventory (TABLES 1 and 2).
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TABLE 1 Clinical classification of rare arrhythmogenic and conduction disorders, and rare arrhythmias. Group 1. Primary electrical disorders of 
the heart, divided into subgroups (A–C and other).
Subgroup by major disorders and arrhythmias RCDD code  ICD ‑10 codea ORPHA numbera
A. Disorders predisposing to supraventricular tachyarrhythmias
1. Associated with preexcitation VI ‑1A ‑1 I45.6 –
1.1. Atrial tachyarrhythmia with short PR interval (enhanced 
atrioventricular nodal conduction)
VI ‑1A ‑1.1 844
1.2. Mahaim syndrome VI ‑1A ‑1.2 –
1.0. Other VI ‑1A ‑1.0 –
2. Atypical and/or familial AVNRT VI ‑1A ‑2 I47.1 –
2.1 Slow ‑slow AVNRT VI ‑1A ‑2.1 –
2.2 Fast ‑slow AVNRT VI ‑1A ‑2.2 –
2.0 Other VI ‑1A ‑2.0 –
3. Atypical atrial flutter VI ‑1A ‑3 I48.4 –
4. Idiopathic neonatal atrial flutter VI ‑1A ‑4 P29.1 45 452
5. Sinoatrial reentry tachycardia VI ‑1A ‑5 I49.9 –
6. Multifocal atrial tachycardia VI ‑1A ‑6 I47.1 3282
7. Permanent form of junctional reciprocating tachycardia VI ‑1A ‑7 I47.1 –
8. His bundle tachycardia VI ‑1A ‑8 I47.1 3283
9. Double fire tachycardia VI ‑1A ‑9 I47.1 –
0. Other VI ‑1A ‑0 – –
B. Disorders predisposing to ventricular tachyarrhythmias
1. Channelopathies VI ‑1B ‑1 – –
1.1 Brugada syndrome VI ‑1B ‑1.1 I49.8 130
1.2 Familial long QT syndrome VI ‑1B ‑1.2 I45.8 768
1.3 Familial short QT syndrome VI ‑1B ‑1.3 I49.8 51 083
1.4 Catecholaminergic polymorphic ventricular tachycardia VI ‑1B ‑1.4 I47.2 3286
1.5 Early repolarization syndrome VI ‑1B ‑1.5 I49.8 –
2. Idiopathic ventricular fibrillation VI ‑1B ‑2 I49.0 228 140b
3. Torsades de pointes syndrome with short coupling interval VI ‑1B ‑3 I49.8 51 084
4. Ventricular flutter VI ‑1B ‑4 I49.0 –
5. Idiopathic ventricular tachycardia VI ‑1B ‑5 I47.2 –
6. Bundle branch reentry ventricular tachycardia VI ‑1B ‑6 I47.2 –
7. Incessant infant ventricular tachycardia VI ‑1B ‑7 I47.2 45 453
0. Other VI ‑1B ‑0 –
C. Disorders predisposing to bradyarrhythmias
1. Familial sick sinus syndrome VI ‑1C ‑1 I49.5 166 282
2. Atrial standstill VI ‑1C ‑2 I45.5 1344
3. Congenital heart block VI ‑1C ‑3 I44.2 60 041
4. Familial progressive cardiac conduction defect VI ‑1C ‑4 I45.8 871
0. Other VI ‑1C ‑0 – –
Other
Other VI ‑1O – –
Please note that some RCDDs are not referenced in ICD ‑10. ORPHA numbers are provided from the Orphanet inventory of rare diseases; some RCDDs 
are not referenced in this inventory.
a Sample codes or numbers
b In the Orphanet list of rare diseases and synonyms: idiopathic ventricular fibrillation or familial paroxysmal ventricular fibrillation, non–Brugada type
Abbreviations: AVNRT, atrioventricular nodal reentrant tachycardia; ICD ‑10, International Classification of Diseases, 10th Revision; RCDDs, rare 
cardiovascular diseases and disorders
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As an example, patients with BrS, who are prone 
to ventricular tachycardia or fibrillation, may suf‑
fer from concomitant atrioventricular conduction 
abnormalities, atrial fibrillation, or atrial flut‑
ter.13,43 Importantly, primary arrhythmias may 
either be inherited or acquired and may coincide 
with each other.48,62 Such coincidence increases 
the difficulty of patient management.
Arrhythmias are one of the most frequent man‑
ifestations of heart disease and may be associated 
with increased risk of comorbidities and death.63 
Cardiac arrhythmias are relatively frequent in 
the course of RCDDs and may be secondary to vir‑
tually all RCDDs.64-69 Due to this fact, the RAC‑
DRAs class was moved into class number VI, and 
in the updated RCDDs classification, presumably 
causative or coexistent rare cardiovascular disease 
classes are now listed before RACDRAs. Howev‑
er, as mentioned previously, we did not distin‑
guish a group of arrhythmias secondary to or co‑
existent with RCDDs because the introduction 
of such a group could lead to misclassification of 
the diseases and disorders and influence future 
data on epidemiology and morbidity.4 Another 
reason for this is that a patient may have more 
than one RCDDs. In the interest of epidemiolog‑
ical accuracy, we propose that patients with 2 or 
more RCDDs should be classified using 2 or more 
RCDDs codes. Such patients will probably have 
increased diagnostic and therapeutic difficulties 
when compared with those with a single RCDD. It 
should be noted that arrhythmogenic right ven‑
tricular cardiomyopathy (ORPHA number 247), 
which predisposes patients to ventricular arrhyth‑
mias, is classified in class III of the clinical clas‑
sification of RCDDs—rare diseases of the heart 
(cardiomyopathies).70 Importantly, arrhythmias 
may also result from, or coexist with congenital 
heart defects. In this group of arrhythmias, atrial 
septal defect with atrioventricular conduction de‑
fects (ORPHA number 1479, atrial septal defect‑
‑atrioventricular conduction defects syndrome) 
should be mentioned. This disorder may be asso‑
ciated with both atrioventricular block and atri‑
al fibrillation.71
In the updated classification we introduced 
more iatrogenic causes of arrhythmias into 
the last proposed group, arrhythmias in specific 
clinical settings, as shown in TABLE 2.8,19,72-77 This 
is in light of observed complications of pharma‑
cotherapy and more common invasive cardio‑
vascular treatments.78,79 Furthermore, another 
goal was to increase awareness among physicians 
about possible rare complications of these treat‑
ments. This group of rare heart rhythm distur‑
bances and / or arrhythmias in rare clinical set‑
tings highlights the need to consider challeng‑
es associated with rare and / or specific concom‑
itant clinical conditions.80 Moreover, we do not 
possess detailed data on the prevalence, preven‑
tion, and management of such conditions.5,6,81,82 
We introduced an example of fatty acid oxidation 
disorders in the subgroup of metabolic disorders 
because in these clinical entities potentially lethal 
advanced interatrial block at baseline was ob‑
served in 0.5% of persons.
Within the subgroup of disorders potentially 
associated with ventricular tachyarrhythmias, 
several examples of inherited arrhythmogenic 
disorders were listed. These included channelo‑
pathies: BrS, familial long QT syndrome, familial 
short QT syndrome, and catecholaminergic poly‑
morphic ventricular tachycardia.42-49 Moreover, 
idiopathic ventricular fibrillation and torsades de 
pointes syndrome with a short coupling interval 
are also included as major disorders.50,51 We also 
included incessant infant ventricular tachycar‑
dia in the subgroup of disorders predisposing to 
ventricular tachyarrhythmias, considering that 
this clinical entity seems to have a heterogeneous 
pathogenesis, including histiocytoid cardiomyop‑
athy and cardiac rhabdomyomas.52-54 Moreover, 
we included early repolarization syndrome (ma‑
lignant early repolarization syndrome), ventricu‑
lar flutter, idiopathic ventricular tachycardia and 
bundle branch reentry ventricular tachycardia in 
this subgroup.55-58
The subgroup of rare disorders associated 
with bradyarrhythmias includes familial sick si‑
nus syndrome,59 atrial standstill,60,61 congeni‑
tal heart block,54 and familial progressive cardi‑
ac conduction defect. It should be emphasized 
that in patients with rare arrhythmias, other co‑
existing heart rhythm disturbances may be ob‑
served, but in the clinical classification, it is pro‑
posed to indicate the most significant arrhyth‑
mia or that which poses the greatest threat to 
the patient (major clinical presentation or risk). 
TABLE 2 Clinical classification of rare arrhythmogenic and conduction disorders, and 
rare arrhythmias. Group 2. Arrhythmias in specific clinical settings, divided into 
subgroups (A, B, and other).
Subgroups by major disorders and 
arrhythmias
RCDD code ICD ‑10 codea ORPHA 
numbera
A. Iatrogenic or related to medical treatment
1. Complication of pharmacotherapy VI ‑2A ‑1 Z51.1 –
2. After surgical or invasive 
correction of heart diseases or 
disorders
VI ‑2A ‑2 Y83 –
3. After heart transplantation VI ‑2A ‑3 Z94.1 –
4. After ablation of arrhythmias VI ‑2A ‑4 – –
5. After cardiovascular implantable 
electronic devices placement
VI ‑2A ‑5 Z95.0
Z95.8
–
0. Other VI ‑2A ‑0 – –
B. Metabolic disorders
1. Fatty acid oxidation disorders VI ‑2B ‑1 E71.3 157
0. Other VI ‑2B ‑0 – –
Other
Other VI ‑2O – –
Please note that some RCDD are not referenced in ICD ‑10. ORPHA numbers are 
provided from the Orphanet inventory of rare diseases; some RCDD are not referenced 
in this inventory.
a Sample codes or number
Abbreviations: see TABLE 1
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contractions arising from the right ventricular outflow tract: is implant‑
able cardioverter ‑defibrillator indicated? Pol Arch Intern Med. 2018; 128: 
166‑170.
9 Ludwik B, Deutsch K, Mazij M, et al. Electrocardiographic algorithms to 
guide the management strategy of idiopathic outflow tract ventricular ar‑
rhythmias. Pol Arch Intern Med. 2017; 127: 749‑757. 
10 Decision No 1295/1999/EC of the European Parliament and of 
the Council of 29 April 1999 adopting a programme of Community action 
on rare diseases within the framework for action in the field of public health 
(1999 to 2003). Official Journal of the European Union. 1999; L 155: 1‑6.
11 List of rare diseases and synonyms: listed in alphabetical order. Or‑
phanet Report Series, Rare Diseases collection, June 2017, http://www.or‑
pha.net/orphacom/cahiers/docs/GB/List_of_rare_diseases_in_alphabetical_
order.pdf. Accessed November 25, 2017.
12 Matusik PT, Pudło J, Rydlewska A, et al. Brugada syndrome: current 
diagnostics, epidemiology, genetic data and novel mechanisms (RCD code: 
V ‑1A.1). J Rare Cardiovasc Dis. 2017; 3: 73‑80.
13 Matusik PT, Komar M, Podolec J, et al. Exercise ECG unmasked Bruga‑
da sign: manifestation of the risk of sports ‑associated sudden cardiac arrest 
(RCD code: V ‑1A.1). J Rare Cardiovasc Dis. 2017; 3: 92‑97.
14 International Statistical Classification of Diseases and Related 
Health Problems 10th Revision. http://apps.who.int/classifications/icd10/
browse/2016/en. Accessed October 8, 2017.
15 Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Asso‑
ciation (EHRA) consensus document on the management of supraventricu‑
lar arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia ‑Pacific Heart 
Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion 
Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017; 19: 465‑511. 
16 Kim IS, Sohn J, Lee SJ, et al. Association of air pollution with increased 
incidence of ventricular tachyarrhythmias recorded by implantable cardio‑
verter defibrillators: vulnerable patients to air pollution. Int J Cardiol. 2017; 
240: 214‑220. 
17 Issa ZF, Miller JM, Zipes DP. Clinical arrhythmology and electrophysi‑
ology: a companion to Braunwald’s heart disease. 1st ed. Philadelphia, PA: 
Saunders Elsevier; 2009.
18 Barstow C, McDivitt JD. Cardiovascular disease update: bradyarrhyth‑
mias. FP Essent. 2017; 454: 18‑23.
19 Brignole M, Auricchio A, Baron ‑Esquivias G, et al. 2013 ESC Guidelines 
on cardiac pacing and cardiac resynchronization therapy: the Task Force 
on cardiac pacing and resynchronization therapy of the European Society 
of Cardiology (ESC). Developed in collaboration with the European Heart 
Rhythm Association (EHRA). Eur Heart J. 2013; 34: 2281‑2329.
20 Priori SG, Blomstrom ‑Lundqvist C, Mazzanti A, et al. 2015 ESC Guide‑
lines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death: The Task Force for the Management 
of Patients with Ventricular Arrhythmias and the Prevention of Sudden Car‑
diac Death of the European Society of Cardiology (ESC). Endorsed by: Asso‑
ciation for European Paediatric and Congenital Cardiology (AEPC). Eur Heart 
J. 2015; 36: 2793‑2867. 
21 Ravina T, Lapuerta JA, Gutierrez J. Atrial fibrillation in the Mahaim syn‑
drome: atrial pacing and adenosine ‑induced AV block to unmask a Mahaim 
physiology. Int J Cardiol. 1999; 71: 189‑192. 
22 Basso C, Corrado D, Rossi L, et al. Ventricular preexcitation in children 
and young adults: atrial myocarditis as a possible trigger of sudden death. 
Circulation. 2001; 103: 269‑275. 
23 Jimenez ‑Diaz J, Gonzalez ‑Marin MA, Gonzalez ‑Ferrer JJ, et al. Long 
RP interval tachycardia. What is the mechanism? J Arrhythm. 2017; 33: 
242‑244. 
24 Bradley DJ, Fischbach PS, Law IH, et al. The clinical course of mul‑
tifocal atrial tachycardia in infants and children. J Am Coll Cardiol. 2001; 
38: 401‑408. 
25 Brugada J, Blom N, Sarquella ‑Brugada G, et al. Pharmacological and 
non ‑pharmacological therapy for arrhythmias in the pediatric population: 
EHRA and AEPC ‑Arrhythmia Working Group joint consensus statement. Eu‑
ropace. 2013; 15: 1337‑1382. 
26 Orejarena LA, Vidaillet H, Jr., DeStefano F, et al. Paroxysmal supra‑
ventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 
31: 150‑157. 
27 Katritsis DG, Sepahpour A, Marine JE, et al. Atypical atrioventricular 
nodal reentrant tachycardia: prevalence, electrophysiologic characteristics, 
and tachycardia circuit. Europace. 2015; 17: 1099‑1106. 
28 Adusumalli S, Gluer R, Lee A, et al. Double fire tachycardia induced 
cardiomyopathy: first ever reported case in Australia. Intern Med J. 2017; 
47: 468‑470. 
29 Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Asso‑
ciation (EHRA) consensus document on the management of supraventricu‑
lar arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia ‑Pacific Heart 
Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion 
Cardiaca y Electrofisiologia (SOLAECE). Eur Heart J. 2018; 39: 1442‑1445.
30 Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial 
flutter in the general population. J Am Coll Cardiol. 2000; 36: 2242‑2246. 
31 Simmers TA, Sreeram N. Sinoatrial reentry tachycardia: a review. Indi‑
an Pacing Electrophysiol J. 2003; 3: 109‑116.
arrhythmias may occur as the first symptom with‑
out associated cardiomyopathy.83 This highlights 
the fact that metabolic alterations may affect car‑
diac electrophysiology.84
Limitations of the classification of rare arrhythmogen-
ic and conduction disorders, and rare arrhythmias It 
should be noted that this updated classification 
has potential limitations and may still require 
revision. We are open to comments and sugges‑
tions to further improve it in the future. Physi‑
cians or researchers who believe that any other 
disease or disorder should be included into RAC‑
DRAs are encouraged to write to the correspond‑
ing author of the classification, including the rea‑
sons for inclusion and the prevalence of a disor‑
der or disease in the general population. 
Conclusion The updated clinical classification of 
RACDRAs may be used to facilitate further re‑
search and progress in clinical practice, both for 
diagnostic and therapeutic purposes. 
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